Could Buying RKLB Before the SpaceX IPO Set You Up for Life?

The article argues SpaceX's planned IPO is overvalued at a $2 trillion target, or 107x last year's sales, and highlights a $4.3 billion Q1 2026 net loss on $4.7 billion of revenue after xAI integration. It contrasts that with Rocket Lab's 38% 2025 revenue growth to $602 million and analyst expectations for 38% CAGR through 2028, EBITDA positivity in 2027, and GAAP profitability in 2028. Overall, it is a valuation-driven comparison piece that is negative on SpaceX and cautiously constructive on Rocket Lab.

Analysis

The main market implication is not the SpaceX IPO itself, but the re-rating pressure it creates across the private and public space stack. A 100x-plus sales anchor for the category can lift all boats briefly, but it also raises the bar for any listed peer to prove it deserves growth-stock multiples rather than hardware/launch multiples. That matters for Rocket Lab: the market may keep rewarding narrative momentum in the near term, but at this valuation the stock becomes extremely sensitive to any execution slip on Neutron, margin progression, or contract timing.

The more important second-order effect is capital allocation discipline. SpaceX’s AI losses imply that investors are being asked to fund a conglomerate-style burn profile inside a space pure-play wrapper, which should make profitable or near-breakeven adjacent names look cleaner by comparison. That creates a relative-value tailwind for public defense-space beneficiaries like SDA-related contractors and selected small-cap payload/security names, especially if investors rotate toward businesses with clearer procurement visibility and less balance-sheet ambiguity.

Near term, the catalyst path is crowded: IPO hype can continue for weeks, but once the deal is priced, the market will likely refocus on whether post-listing fundamentals justify the premium. The main risk to the bearish IPO framing is that scarcity and retail flow overpower valuation discipline for longer than expected. The counterpoint on Rocket Lab is that a still-early earnings inflection can support multiple expansion for months if launch cadence improves and services mix keeps rising; the bear case only works if execution stalls before the market gets to 2027 profitability milestones.

The contrarian miss is that the best trade may not be short SpaceX or long RKLB outright, but owning the enablers of the broader space buildout: subsystems, defense payload, and specialty materials. If SpaceX remains constrained by capital intensity while Rocket Lab scales, the ecosystem winners may capture the most durable operating leverage without needing heroic valuation assumptions.

Key Decisions for Investors

• Long RKLB on pullbacks over the next 2-6 weeks; use a phased entry because near-term IPO sentiment can keep the stock overbought, but a 12-18 month horizon still supports upside if Neutron stays on schedule. Risk/reward improves materially if it de-risks execution before the IPO pop fades.
• Avoid chasing the SpaceX IPO on day one; if accessible, prefer waiting for first-lockup/post-listing volatility rather than paying the opening scarcity premium. The risk is permanent multiple compression once the market digests the burn profile.
• Pair trade: long RKLB / short a basket of high-multiple private-space proxies or unprofitable space-adjacent names on any retail-led surge. The thesis is multiple normalization: cleaner balance sheets should outperform once fundamentals reassert over narrative.
• Watch SDA-linked beneficiaries and defense-space subcontractors for a delayed re-rating over 1-3 months; add on confirmation of procurement flow rather than headline hype. These names can benefit from increased space budget attention without taking SpaceX-style valuation risk.
• Sell upside calls against RKLB into strength if it continues to gap on SpaceX headlines; valuation leaves limited margin for error and call overwrites can monetize hype-driven volatility while preserving core upside.